Osteoporosis Screening and Treatment in Women with Schizophrenia: A Controlled Study

Pharmacotherapy

Volumn 24, Issue 4, 2004, Pages 515-521

  Bishop, Jeffrey R ^a   Alexander, Bruce ^a,b   Lund, Brian C ^c   Klepser, Teresa B ^d,e  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Pharmacy ^*  (United States)

^c Laureate Psychiatric Clinic and Hospital   (United States)

^d FERRIS STATE UNIVERSITY   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Osteoporosis screening; Osteoporosis treatment; Schizophrenia

Indexed keywords

HORMONE;

ADULT; AGED; ALCOHOL CONSUMPTION; CLINICAL FEATURE; CONTROLLED STUDY; COUNSELING; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

AGED; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1842532193     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.5.515.33346     Document Type: Review

References (40)

1. Karasu TB, Waltzman SA, Lindenmayer JP, Buckley PJ. The medical care of patients with psychiatric illness. Hosp Community Psychiatry 1980;31:463-72.
2. Koranyi EK. Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Arch Gen Psychiatry 1979;36:414-19.
3. Koran LM, Sox HC, Marton KI, et al. Medical evaluation of psychiatric patients. I. Results in a state mental health system. Arch Gen Psychiatry 1989;46:733-40.
4. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516-20.
5. Berren MR, Santiago JM, Zent MR, Carbone CP. Health care utilization by persons with severe and persistent mental illness. Psychiatr Serv 1999;50:559-61.
6. Druss BG, Rosenheck RA. Use of medical services by veterans with mental disorders. Psychosomatics 1997;38:451-8.
7. Dickerson FB, Pater AP, Origoni AE. Health behaviors and health status of older women with schizophrenia. Psychiatr Serv 2002;53:882-4.
8. Lindamer LA, Buse DC, Auslander L, Unutzer J, Bartels SJ, Jeste DV. A comparison of gynecological variables and service use among older women with and without schizophrenia. Psychiatr Serv 2003;54:902-4.
9. Druss BG, Rosenheck RA, Desai MM, Perlin JB. Quality of preventive medical care for patients with mental disorders. Med Care 2002;40:129-36.
10. Daumit GL, Crum RM, Guallar E, Ford DE. Receipt of preventive medical services at psychiatric visits by patients with severe mental illness. Psychiatr Serv 2002;884-7.
11. National Osteoporosis Foundation. Physician's guide to the treatment and prevention of osteoporosis. Belle Mead, NJ: Excerpta Medica Inc; 1999.
12. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57:485-91.
13. Abraham G, Friedman RH, Verghese C, de Leon J. Osteoporosis and schizophrenia: can we limit known risk factors? Biol Psychiatry 1995;38:131-2.
14. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526-8.
15. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
16. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003;326:322-6.
17. U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions. Ann Intern Med 2002;137:834-9.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
19. South-Paul JE. Osteoporosis. I. Evaluation and assessment. Am Fam Physician 2001;63:897-904.
20. National Institutes of Health. Osteoporosis prevention, diagnosis and therapy. NIH Consens Statement 2000;17:1-45.
21. Brown S, Birtwistle J, Roe J, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.
22. Osborn DP. The poor physical health of people with mental illness. West J Med 2001;175:329-32.
23. Gopalaswamy AK, Morgan R. Smoking in chronic schizophrenia [letter]. Br Brj Psychiatry 1986;149:523.
24. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7.
25. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA 1990;264:2511-18.
26. Vieweg V, Levenson J, Pandurangi A, Silverman J. Medical disorders in the schizophrenic patient. Int J Psychiatry Med 1995;25:137-72.
27. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994;330:387-92.
28. Zhang-Wong JH, Seeman MV. Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arc Women Ment Health 2002;5:93-8.
29. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35:S75-86.
30. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(suppl 1):53-67.
31. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-5.
32. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(suppl 2):55-68.
33. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003;28(suppl 2):69-82.
34. Baastrup PC, Christiansen C, Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980;6:56-9.
35. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002;112: 817-28.
36. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28:97-108.
37. Delva NJ, Crammer JL, Jarzylo SV, et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 1989;26:781-93.
38. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996;22:447-54.
39. de Leon J, Verghese C, Tracy JI, Josiassen RC, Simpson GM. Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol Psychiatry 1994;35:408-19.
40. Abraham G, Freidman RH, Verghese C. Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry 1996;40:430-1.